In utero resolution of microcystic congenital cystic adenomatoid malformation after prenatal betamethasone therapy: A report of three cases and a literature review | Zendy

Yamashita Akiko | Zendy; Hidaka Nobuhiro | Zendy; Yamamoto Ryo | Zendy; Nakayama Soichiro | Zendy; Sasahara Jun | Zendy; Ishii Keisuke | Zendy; Mitsuda Nobuaki | Zendy

Premium

In utero resolution of microcystic congenital cystic adenomatoid malformation after prenatal betamethasone therapy: A report of three cases and a literature review

Author(s) -

Yamashita Akiko,

Hidaka Nobuhiro,

Yamamoto Ryo,

Nakayama Soichiro,

Sasahara Jun,

Ishii Keisuke,

Mitsuda Nobuaki

Publication year - 2015

Publication title -

journal of clinical ultrasound

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.272

H-Index - 61

eISSN - 1097-0096

pISSN - 0091-2751

DOI - 10.1002/jcu.22214

Subject(s) - betamethasone , medicine , in utero , fetus , gestation , congenital cystic adenomatoid malformation , gestational age , obstetrics , hydrops fetalis , prenatal diagnosis , ultrasound , survival rate , pregnancy , gynecology , surgery , radiology , biology , genetics

Fetal congenital cystic adenomatoid malformation (CCAM) can progress to nonimmune hydrops, and the mortality rate of CCAM with hydrops is reported to be nearly 100%. We describe three microcystic CCAM cases in which the fetal condition improved after maternal betamethasone therapy. The median gestational age at steroid administration was 23 5/7 weeks' gestation. The CCAM decreased in size in all cases. Our series showed a 100% hydrops resolution rate (2/2) and a 100% survival rate (3/3). Our experience suggests the efficacy of betamethasone treatment on fetuses with microcystic CCAM who have fluid collection or are at risk of developing hydrops. © 2014 Wiley Periodicals, Inc. J Clin Ultrasound 43 :451–457, 2015

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research